Yazar "Erdoğan, Bülent" için listeleme
-
Comparison of skeletal muscle mass loss in patients with metastatic colorectal cancer treated with regorafenib or TAS-102
Hacıoğlu, Muhammet Bekir; Köstek, Osman; Kurt, Nazmi; Küçükarda, Ahmet; Gökyer, Ali; Ustabaşıoğlu, Fethi Emre; Karataş, Fatih; Tunçbilek, Nermin; Uzunoǧlu, Sernaz; Bilici, Ahmet; Çiçin, İrfan; Erdoğan, Bülent (Zerbinis Publications, 2019)Purpose: To assess whether regorafenib and TAS-102 treatments are associated with a change in Skeletal Muscle Area (SMA) as well as to compare Skeletal Muscle Mass (SMM) loss levels between regorafenib and TAS-102 treatments ... -
Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey
Hacıoğlu, Muhammet Bekir; Köstek, Osman; Karabulut, Senem; Taştekin, Didem; Sezgin Göksu, Sema; Alandağ, Celal; Akagündüz, Baran; Bilgetekin, İrem; Caner, Burcu; Şahin, Ahmet Bilgehan; Yıldız, Birol; Köse, Fatih; Kaplan, Muhammet Ali; Gülmez, Ahmet; Doğan, Ender; Güven, Deniz Can; Gürbüz, Mustafa; Ergun, Yakup; Karaağaç, Mustafa; Demiray, Atike Gökçen; Türker, Sema; Sakalar, Teoman; Özkul, Özlem; Akın Telli, Tuğba; Şahin, Süleyman; Kılıçkap, Saadettin; Bilici, Ahmet; Erdoğan, Bülent; Çiçin, İrfan (Imprimatur Publication, 2020)Purpose: After failure of the first-line sorafenib treatment in advanced or metastatic stage hepatocellular carcinoma (HCC), regorafenib is one of the newly-approved targeted agents. We aimed to evaluate the efficacy of ... -
Major and minor salivary gland cancers: A multicenter retrospective study
Hacıoğlu, Muhammet Bekir; Erdoğan, Bülent; Bardakçı, Murat; Algın, Efnan; Gülbağcı, Burcu; Hacıbekiroğlu, İlhan; Hamdard, Jamshid; Ölmez, Ömer Fatih; Akkuş, Hadi; Çiçin, İrfan (John Wiley and Sons Inc, 2023)BackgroundMost of the studies on salivary gland cancers are limited for various reasons such as being single-center, small number of patients, including only major or minor SGCs, or only including epidemiological data. ... -
Treatment preferences in stage IA and IB testicular seminoma: Multicenter study of anatolian society of medical oncology
Bilici, Ahmet; Öztürk, Türkan; Türkmen, Esma; Odabaş, Hatice; Cihan, Şener; Selçukbiricik, Fatih; Erdoğan, Bülent; Urakçı, Zuhat; Kandemir, Nurten; Bayoğu, İbrahim Vedat; Demirci, Umut; Ocak Duran, Ayşe; Şendur, Mehmet Ali; Yavuzer, Dilek; Harputluoğlu, Hakan; Kavgacı, Halil; Gümüş, Mahmut (Springer, 2015)Approximately 75 % of patients with testicular seminoma present with stage I disease, and the probability of long-term survival approaches 100 %. However, the standard adjuvant treatment for stage I seminoma patients remains ...